See Pharvaris NV's analyst price targets ($54) vs the current share price.
Get informed when a big investor buys or sells
+ Follow$33.87
4 analysts in the last 4 months
High: $74 | Low: $42
No recommendations in the last 4 months.
Pharvaris NV posts a target price of $54. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
A target price of $54 for PHVS means covering analysts, on average, see the stock 60.2% upside of $33.87 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.
Context for PHVS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Pharvaris NV's other metric pages and overview cover the third.
Judging Pharvaris NV against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $54 here, then scan peer and history charts to see if the gap is persistent.